The XF Drug pipeline has benefitted from an active programme of collaborative research investigating respiratory, dermal, oral and ocular infections including those associated with biofilms. These projects were academic, commercial and collaborations funded through non-dilutive funding. XF drugs have demonstrated efficacy in preclinical models of biofilm infection from multiple active collaborations in this space:
A research collaboration with Aston University investigating novel compounds from the XF drug platform and their potential to prevent, control and eradicate dangerous bacteria in biofilms.
The National Biofilms Innovation Centre (NBIC) funded a research collaboration with Southampton University examining the utility of the XF drug platform for prevention, control, and eradication if chronic clinical infections with underlying biofilm involvement, such as those in diabetic foot ulcers and cystic fibrosis.
The Global AMR Innovation Fund (GAMRIF) awarded a grant to collaborate with Cardiff University and Tianjin Medical University, China investigating the potential of the XF drug platform for the treatment of dermal and ocular infections and also supported the development of novel dermal and ophthalmic formulations for clinical use.
Further NBIC funded collaborations were awarded in partnership with Sheffield University and Cardiff University to establish the potential of the XF drug platform as novel treatments for drug-resistant ocular infections and oral fungal infections.